Built on Oxford University machine-learning expertise and clinical studies conducted with the Royal Veterinary College, Marley is developing validated pet-health biomarkers grounded in veterinary science to help vets and pet owners see how disease emerges and changes between visitsMarley is setting a new scientific standard for trusted AI-enabled pet-health intelligence, using clinical-grade data, benchmark comparison, and veterinary review to translate animal health signals into insightFounded by leaders from Johnson & Johnson, the Royal Veterinary College, and Oxford clinical machine learning, Marley applies human healthcare science to veterinary care to support more proactive, data-informed care for pets and the clinicians who treat them

LONDON, June 30, 2026 /PRNewswire/ — Marley Health, a clinical intelligence company applying human healthcare science to pet health, today launched to support more proactive, data-informed veterinary care. The company is adapting AI, signal processing, biomarker development, and physiological measurement methods from human healthcare to veterinary medicine, using clinical data from studies conducted with veterinary patients at the Royal Veterinary College (RVC) and machine-learning expertise from the University of Oxford. Marley’s platform is designed to translate complex animal health signals into clinically grounded insight, giving veterinarians and pet owners a more objective way to understand current health status and how health changes over time.

As pets are increasingly treated as family members, the market for pet health technology is moving beyond location tracking and activity scores toward increasingly ambitious claims about health, behavior, and disease. But the evidence standards behind those claims remain uneven. In a lightly-regulated category, pet owners are often asked to trust health information without knowing how it was validated, while veterinarians are left to determine whether data generated outside the clinic is accurate, relevant, and useful for care. That creates a clear need for pet-health intelligence built with the same discipline expected in clinical settings: measured against accepted standards, grounded in veterinary expertise, and designed to support the relationship between clinicians, pets and owners.

Marley’s first product will pair a purpose-built, pet-friendly smart collar with veterinary and pet-owner digital platforms, using the collar to capture data for the company’s broader clinical intelligence layer. The platform is being built to establish and track biomarkers such as gait, posture, resting heart rate, and respiratory rate, with future work focused on more advanced indicators common in human health but still emerging in veterinary medicine.

For veterinarians, Marley is designed to make clinically relevant changes easier to see and follow over time, while providing clearer context on a pet’s current health status against clinical benchmarks. The underlying insights are developed with the RVC’s clinical input, giving veterinarians accurate, relevant information they can use in care. For pet owners, Marley can help clarify when something may be changing, how to best manage their pet’s health, and when a veterinary conversation may be needed.

“Veterinarians do not need more data for its own sake. They need information that is accurate, clinically relevant, and capable of helping them understand what is happening with the animal in front of them,” said Dr. Amanda Boag, Co-Founder and Chief Medical Officer of Marley Health. “That is the standard Marley is building toward. Pet health technology has enormous potential, but it will only earn a meaningful place in veterinary care if the science is rigorous, the data is validated, and the insights are useful in real-world clinical decision-making.”

Marley is preparing to pilot its platform with veterinary organizations in the UK, using early deployments to refine clinical workflow, pet-owner experience, and the validation process behind its biomarker development. As its dataset expands, Marley plans to advance from initial biomarker work into more sophisticated indicators, while building toward clinical decision-support capabilities grounded in RVC validation and machine-learning expertise from Oxford’s Computational Health Informatics Lab.

“Clinically useful AI starts with a clear understanding of the question being asked, the signal being measured, and the standard it is being measured against,” said David Clifton, Co-Founder and Technology Advisor at Marley Health, and Royal Academy of Engineering Chair Professor of Clinical Machine Learning at the University of Oxford. “Marley is applying that discipline to pet health by combining continuous data from daily life with carefully collected animal data and clinical reference points. That approach can help identify patterns that are meaningful for the individual animal and turn longitudinal measurement into insight that veterinarians can use.”

“Marley was founded on the belief that pet care can benefit from the same scientific and technological advances that have changed what is possible in human health,” said Nate Notwell, Co-Founder and CEO of Marley Health. “The goal is to build a company that helps veterinarians and owners understand pet health with more objectivity, more context, and more confidence over time. That starts with validated biomarkers, but the larger opportunity is creating the clinical intelligence layer that allows pet care to become more proactive, more precise, and more connected to what is happening in an animal’s day-to-day life.”

About Marley Health
Marley Health is a clinical intelligence company applying human healthcare science to pet health. Founded by leaders from Johnson & Johnson, the Royal Veterinary College (RVC), and Oxford’s clinical machine learning community, Marley develops validated pet-health biomarkers designed to give veterinarians and pet owners a more objective view of an animal’s current health status, and how health changes over time. The company combines machine-learning expertise, clinical studies conducted with the RVC, and veterinary science to translate complex animal health signals into clinically grounded insight for use in veterinary care and at home. For more information, visit marleyhealth.com.

Media contact:
marley@hermespr.co

View original content to download multimedia:https://www.prnewswire.com/news-releases/marley-health-launches-to-build-the-clinical-intelligence-layer-for-proactive-pet-care-302814045.html

SOURCE Marley Health

Firm-wide deployment standardizes money-in-motion intelligence across $17 billion, 14-office national RIA

NEW YORK, June 30, 2026 /PRNewswire/ — WealthFeed, an AI-powered prospecting and organic growth platform for financial advisors, today announced that The Mather Group, LLC (TMG) has named WealthFeed its sole approved enterprise prospecting platform.

Headquartered in Chicago and founded in 2011, TMG is a fee-only, planning-led national wealth manager serving high-net-worth and ultra-high-net-worth families. The firm advises on approximately $17 billion in client assets, is recognized on Barron’s Top 100 RIA Firms list and has completed more than 20 acquisitions since 2018. The agreement continues WealthFeed’s growth in the RIA space.

Through the partnership, TMG’s approximately 100 advisors across 14 offices will have firm-wide access to WealthFeed’s platform for real-time money-in-motion intelligence, warm introduction paths, data enrichment, compliant outreach and inbound web lead capture. The platform will help advisors identify signals tied to inheritances, liquidity events, business sales, promotions and retirements, while surfacing prospects they may already be connected to.

“When I was on the advisory side of the business, I saw that meaningful client opportunities often started with a life event that results in assets changing hands,” said Sam Kendree, CEO and Co-Founder of WealthFeed. “Those moments create a window for advisors to become part of the conversation. We built WealthFeed to help advisors recognize when that window is opening and act while they still have a chance to provide professional guidance and shape the decision.”

The WealthFeed platform deployment helps establish a standardized prospecting framework across TMG’s offices, giving the firm’s current advisors and recently acquired teams a single, consistent process for identifying high-intent prospects and money-in-motion opportunities.

“As we’ve grown into a national firm with 14 offices, we’ve focused on building infrastructure that lets every advisor across TMG operate with the same level of discipline and capability,” said Deana Lewis, Chief Marketing Officer at The Mather Group. “Naming WealthFeed our exclusive prospecting platform is a major element of our organic growth strategy. It gives our advisors a single source of money-in-motion intelligence and a consistent framework for identifying and engaging the right prospects across every office.”

The agreement builds on WealthFeed’s growing enterprise momentum following its 2025 strategic partnership and minority investment from Broadridge Financial Solutions, which combined WealthFeed’s money-in-motion intelligence with Broadridge’s advisor marketing capabilities.

About WealthFeed
WealthFeed is an AI-powered prospecting and growth platform built for financial advisors. The platform helps advisors identify money-in-motion opportunities, enrich prospect data and automate outreach through a single integrated system. WealthFeed serves independent advisors, RIAs and wealth management enterprises across the United States. For more information, visit wealthfeed.com.

Media Contacts
Grant Cox / Elizabeth Shim
Haven Tower Group LLC
424 317 4852 or 424 317 4861
gcox@haventower.com or eshim@haventower.com

View original content:https://www.prnewswire.com/news-releases/wealthfeed-selected-by-the-mather-group-as-exclusive-prospecting-platform-302812735.html

SOURCE WealthFeed

Company Holds Approximately 780.4838 Bitcoin and 10,000 Ounces of Silver as it Advances its AI Data Center and Robotics Operations

LAS VEGAS, June 30, 2026 /PRNewswire/ — Hyperscale Data, Inc. (NYSE American: GPUS), an artificial intelligence (“AI”) data center company anchored by Bitcoin (“Hyperscale Data” or the “Company”), today announced that, as of June 29, 2026, the combined value of the Company’s Bitcoin, cash, restricted cash, and .999 silver was approximately $106.7 million.

Based upon the closing price of the Company’s common stock on June 29, 2026, the $106.7 million in Bitcoin, cash, restricted cash, and .999 silver represents approximately 117.06% of the current market capitalization of the Company.

In aggregate, the Company’s wholly owned subsidiaries, Sentinum, Inc. (“Sentinum”) and Ault Capital Group, Inc. (“ACG”), held 780.4838 Bitcoin as of June 29, 2026. Between June 21, 2026 and June 29, 2026, ACG purchased approximately 49.2490 Bitcoin in the open market. Based on the Bitcoin closing price of $60,138 on June 29, 2026, these collective holdings had an approximate market value of $46.9 million.

“In my view, the market reaction has been completely disconnected from the facts,” stated Milton “Todd” Ault III, Executive Chairman of Hyperscale Data. “Hyperscale Data has reported Bitcoin, cash, restricted cash and silver holdings of approximately $106.7 million, while we continue to advance our Michigan AI data center strategy, robotics platform and Bitcoin treasury initiatives. We believe the current market capitalization of the common stock fails to reflect the value of the Company’s reported assets, its operating businesses and the magnitude of the opportunity before us after the recent signing of the transformational master services agreement at its Michigan AI data center.”

For more information on Hyperscale Data and its subsidiaries, Hyperscale Data recommends that stockholders, investors and any other interested parties read Hyperscale Data’s public filings and press releases available under the Investor Relations section at hyperscaledata.com or available at www.sec.gov.

About Hyperscale Data, Inc.

Through its wholly owned subsidiary Sentinum, Hyperscale Data owns and operates a data center at which it mines digital assets and offers colocation and hosting services for the emerging AI ecosystems and other industries. Hyperscale Data’s other wholly owned subsidiary, ACG, is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact.

Hyperscale Data currently expects the divestiture of ACG (the “Divestiture”) to occur in the second quarter of 2027. Upon the occurrence of the Divestiture, the Company would be an owner and operator of data centers to support high-performance computing services, as well as a holder of the digital assets. Until the Divestiture occurs, the Company will continue to provide, through ACG and its wholly and majority-owned subsidiaries and strategic investments, mission-critical products that support a diverse range of industries, including an AI software platform, equipment rental services, defense/aerospace, industrial, automotive and hotel operations. In addition, ACG is actively engaged in private credit and structured finance through Ault Lending, LLC, a licensed lending subsidiary. Hyperscale Data’s headquarters are located at 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141.

On December 23, 2024, the Company issued one million (1,000,000) shares of a newly designated Series F Exchangeable Preferred Stock (the “Series F Preferred Stock”) to all common stockholders and holders of the Series C Preferred Stock on an as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of Class A Common Stock and Class B Common Stock of ACG (collectively, the “ACG Shares”). The Company reminds its stockholders that only those holders of the Series F Preferred Stock who agree to surrender such shares, and do not properly withdraw such surrender, in the exchange offer through which the Divestiture will occur, will be entitled to receive the ACG Shares and consequently be shareholders of ACG upon the occurrence of the Divestiture.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties.

Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at hyperscaledata.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hyperscale-data-bitcoin-treasury-cash-restricted-cash-and-silver-holdings-of-approximately-106-7-million-represents-117-06-of-current-market-capitalization-of-common-stock-302814072.html

SOURCE Hyperscale Data Inc.